Breaking News
September 21, 2018 - Young children’s oral microbiota could serve as early indicator for obesity
September 21, 2018 - Older individuals with multiple sclerosis report higher quality of life than younger counterparts
September 21, 2018 - LineaRx signs agreement with Takis/Evvivax to develop linear-DNA based anti-cancer vaccines
September 21, 2018 - AbbVie Presents Upadacitinib Longer-Term (32-Week) and Patient-Reported Outcomes Data from Phase 2b Atopic Dermatitis Study at 27th European Academy of Dermatology and Venereology (EADV) Congress
September 21, 2018 - Alzheimer’s drug may stop disease if used before symptoms develop
September 21, 2018 - Human skeletal stem cell can generate cartilage, bone
September 21, 2018 - UK and European research collaborations receive vote of confidence by three major cancer charities
September 21, 2018 - Microbiota in the intestines and cell stress cause colon cancer
September 20, 2018 - Arizona EMTs have 39% higher risk for suicide than general public
September 20, 2018 - Driving and older adults: MedlinePlus Medical Encyclopedia
September 20, 2018 - Researchers test autobiographical memory for early Alzheimer’s detection
September 20, 2018 - Organizations join forces to help teens with severe mental health challenges | News Center
September 20, 2018 - Neurons in the human brain can encode numerical information
September 20, 2018 - Potential drugs to treat neurodegenerative diseases garner $3 million grant
September 20, 2018 - Processing speed important to higher order cognitive function in multiple sclerosis patients
September 20, 2018 - Helping a patient survive a hurricane
September 20, 2018 - Tafamidis Treats Transthyretin Amyloid Cardiomyopathy
September 20, 2018 - Low academic achievement can lead to drug abuse decades later, research finds
September 20, 2018 - Study identifies stem cell that gives rise to new bone, cartilage in humans | News Center
September 20, 2018 - Celltrion and Emory University sign ‘Incubation’ agreement to develop new drug candidates for atherosclerosis
September 20, 2018 - TGen and PNOC take part in launch of NIH-supported Kids First Data Resource Portal
September 20, 2018 - Could Household Cleaners Make Your Kid Fat?
September 20, 2018 - Addiction nonprofit makes searching for services simple
September 20, 2018 - We are bombarded by thousands of diverse species and chemicals | News Center
September 20, 2018 - Experts to Present Prostate Cancer Advances at Patient Summit
September 20, 2018 - Alector announces initiation of Phase 1 trial of AL001 for treating frontotemporal dementia
September 20, 2018 - Pfizer’s 20vPnC vaccine receives Breakthrough Therapy designation from FDA
September 20, 2018 - Study could allow doctors to screen patients at risk from Aspergillus
September 20, 2018 - Emergex signs MoU with Brazil’s Fiocruz for development of viral vaccines
September 20, 2018 - The ‘real you’ is a myth – we constantly create false memories to achieve the identity we want
September 20, 2018 - Researchers describe cell mechanism that optimizes proteins production in stressful situations
September 20, 2018 - Cell Medica successfully doses first patient with CMD-501 targeting pediatric neuroblastoma
September 20, 2018 - Sesen Bio to present its three-month Phase 3 VISTA Trial data at Global Congress
September 20, 2018 - Senators unveil legislation to protect patients against surprise medical bills
September 20, 2018 - Study provides insights into development of special-purpose cosmetic products
September 20, 2018 - Research shows enlarged genotype-phenotype correlation for three-base pair deletion in NF1
September 20, 2018 - 91% of people around the world believe medical research will result in dementia cure
September 20, 2018 - DePuy Synthes introduces CONCORDE LIFT Expandable Interbody Device at EUROSPINE 2018
September 20, 2018 - Manx Telecom unveils MT clearSound that improves clarity of mobile phone calls
September 20, 2018 - Mediterranean-style diet appears to reduce stroke risk in women
September 20, 2018 - AbbVie Announces Patient-Reported Outcomes Data from Three Pivotal Phase 3 Studies of Risankizumab, Showing Significant Improvements in Health-Related Quality of Life for Patients with Psoriasis
September 20, 2018 - Characterization of pregnancy microbiome reveals variations in bacterial diversity
September 20, 2018 - New guidance for treatment of bone loss in hematologic stem cell transplant Recipients
September 20, 2018 - Experts to present research on prevention, management of dysphagia at international conference
September 20, 2018 - New study focuses on two-way gene switches controlling gene activity
September 20, 2018 - Zika virus could become a weapon against brain cancer
September 20, 2018 - Home-based video game exercises can reduce chronic low back pain in older people, study finds
September 20, 2018 - Investigators find that bile acids reduce cocaine reward
September 20, 2018 - Cannabinoid drugs reduce perceived unpleasantness of painful stimuli and increase tolerance
September 20, 2018 - Health care companies’ data could enable more accurate flu season forecasts
September 20, 2018 - Geroscience takes center stage in Journal of the American Medical Association
September 20, 2018 - Ambient Particulate Matter Linked to Emergency Asthma Care
September 20, 2018 - Patient satisfaction with plastic surgery—it’s the surgeon, not the practice
September 20, 2018 - Medicine is a team sport – and that’s exactly how it should be
September 20, 2018 - Logos Biosystems releases new electrophoretic tissue clearing system with twice the features in half the space
September 20, 2018 - Novel micro-platform reveals never-before-seen behaviors of cancer cells
September 20, 2018 - PAREXEL partners with Datavant to enhance clinical study design and generate real-world evidence
September 20, 2018 - Robert Koch Institute publishes new data on allergies, mental health problems, and accident injuries
September 20, 2018 - Study finds higher readmission rates in for-profit hospitals
September 20, 2018 - Encouraging youth to do strength-based exercises could help tackle child obesity
September 20, 2018 - Sleep apnea, congenital heart disease in hospitalized infants strongly associated with death
September 20, 2018 - Researchers find way to map mysterious content of non-coding RNA
September 20, 2018 - Air Pollutants Reach Placenta, Might Harm Fetus: Study
September 20, 2018 - Sleep apnea, congenital heart disease may be deadly mix for hospitalized infants
September 20, 2018 - My relative has cancer, should I worry? Encouraging cascade genetic testing
September 20, 2018 - Investigators determine specific treatable traits that can predict future asthma attacks
September 20, 2018 - More doctor visits can lower risk of suicide attempts in fibromyalgia patients
September 20, 2018 - Computer avatars play role in diagnosis of dementia
September 20, 2018 - Addition of CTLA4 targeted therapy to PD-1 targeted therapy may benefit patients with ovarian cancer
September 20, 2018 - ASPREE trial explores whether low dose aspirin can prolong good health in elderly people
September 20, 2018 - ATS publishes new guideline focused on weight loss strategies for sleep apnea patients
September 20, 2018 - The Current issue of “The view from here” is concerned with Drug Delivery
September 19, 2018 - Sleep apnea could favour tumor growth at young ages
September 19, 2018 - Stealth vaping fad hidden from parents, teachers
September 19, 2018 - Witnessing school violence linked to later risk of psycho-social and academic impairment
September 19, 2018 - Common household cleaners could make children overweight by changing gut microbiota
September 19, 2018 - Salk research in yeast leads to serendipitous finding about hypomyelinating leukodystrophy
September 19, 2018 - Study: Overweight or obese women may have increased risk of urinary incontinence
September 19, 2018 - Study shows how cellular waste disposal processes also promote inflammation
September 19, 2018 - New multidisciplinary microsurgery microscope, PROVIDO, introduced by Leica
Altering genetic mutation could enhance FluMist vaccine’s protective effect

Altering genetic mutation could enhance FluMist vaccine’s protective effect

image_pdfDownload PDFimage_print

Researchers at Johns Hopkins Bloomberg School of Public Health have discovered a genetic mutation in the FluMist intranasal flu vaccine that has the potential to be altered to enhance the vaccine’s protective effect.

This flu season marks the second that the panel that advises the Centers for Disease Control and Prevention (CDC) on vaccines has recommended that FluMist not be used in the U.S. The Advisory Committee on Immunization Practice found that the vaccine had grown less effective in recent years, possibly due to shifts in circulating flu strains, and researchers have been searching for ways to restore its effectiveness.

In the new study, the Bloomberg School researchers discovered a previously overlooked mutation, present within two of the viral strains used in the vaccine, that reduces virus production. When the researchers reversed the mutation in one of the viruses, the virus became more active, making copies of itself – which is known as replicating – more quickly in cultured human nasal cells and inducing a stronger production of immune proteins.

The findings appears in the journal Vaccine.

“Only one component of FluMist – the one targeting the Type A H1N1 virus – has been failing in the U.S. recently,” says Andrew S. Pekosz, PhD, professor in the Bloomberg School’s Department of Molecular Microbiology and Immunology. “It’s not clear exactly why it has failed but this mutation we identified could be used to make that component of the vaccine a little stronger, thereby improving vaccine efficacy. We now see the possibility of altering this mutation and perhaps others in the vaccine to optimize the vaccine’s protective effect, perhaps for different age groups.”

Three types of influenza viruses affect people, Type A, Type B and Type C, and flu vaccines include a mix of virus strains tailored to anticipate the upcoming flu season. The CDC estimates that over the past seven years, flu viruses have caused 9.2 million to 60.8 million illnesses, 140,000 to 710,000 hospitalizations, and 12,000 to 56,000 deaths annually in the U.S. Across the globe, there are an estimated three to five million cases of severe flu cases and about 250,000 to 500,000 deaths.

The FluMist vaccine, also known as LAIV (live, attenuated influenza vaccine) is made from four weakened flu virus strains, two representing the influenza A type, and two representing the influenza B type. Two segments of the strains used in the vaccine are altered periodically to match the strains of influenza circulating in the population.

The non-varying parts of the vaccine are made from a special, cold-adapted H2N2 strain that is known to contain mutations that slow its replication at the temperatures found in the human nose and throat. That slowing of activity is largely what keeps these vaccine strains from causing illness in people, although they remain active enough to induce at least partial immune protection against future influenza A infections.

Scientists in previous studies have linked the slower replication of this cold-adapted strain to changes in three virus genes. However, there have been hints in recent years, from Pekosz’s work and others’, that another gene encoding a viral protein called M2 may also contribute to this effect.

“We had studied M2 for years, but one day recently a student in my lab noticed that the M2 in the LAIV influenza A viruses contains a mutation in the same part of the protein that we had previously identified as affecting viral replication,” Pekosz says.

The researchers found that when they introduced this same mutation into a strain of influenza A virus that normally doesn’t have it, the replication rate of the virus dropped. Alternate mutations at the same site on the M2 gene also resulted in a slowing of viral replication.

The team then did the opposite experiment, starting with a FluMist influenza A strain and reversing the M2 mutation. They found that this enhanced the replication rate of the strain in human nasal cells.

The enhanced activity of the virus also led to a jump in production, in infected cells, of the immune protein interferon lambda, indicating an increased immune response. The result showed in principle that this mutation site, and perhaps others on the virus, may be used as “dimmer switches” to adjust the vaccine’s strength up or down–so that it induces a robustly protective immune response without also causing illness.

“What we’re trying to do now is make a panel of these LAIV viruses with different mutations to see if we can boost the replication rates to get vaccine formulations that protect children and other age groups better than LAIV has done in the past few years,” Pekosz says.

Source:

https://www.jhsph.edu/news/news-releases/2017/genetic-mutation-could-if-altered-boost-flumist-vaccine-effectiveness-research-suggests.html

Tagged with:

About author

Related Articles